Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Aytu Bioscience
68.7
%
| 61 | 63.2 % | 74 | 68.7 % | +20.74% |
Aytu Consumer Health
31.3
%
| 36 | 36.8 % | 34 | 31.3 % | -5.48% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
99.6
%
| 95 | 97.9 % | 107 | 99.6 % | +13.01% |
International
0.4
%
| 2 | 2.1 % | 0 | 0.4 % | -76.68% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Mark Oki
DFI | Director of Finance/CFO | 55 | 22-01-16 |
Margaret Cabano
COO | Chief Operating Officer | - | 04-12-31 |
Russell McMahen
CTO | Chief Tech/Sci/R&D Officer | - | 20-12-31 |
Greg Pyszczymuka
PRN | Corporate Officer/Principal | - | 21-12-31 |
Suzane Kennedy
LAW | General Counsel | - | 18-05-31 |
Ryan J. Selhorn
PRN | Corporate Officer/Principal | 42 | - |
Victoria Cordova
HRO | Human Resources Officer | - | 23-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Vivian Liu
BRD | Director/Board Member | 62 | 22-06-30 |
Jarrett Disbrow
FOU | Founder | 49 | 15-04-15 |
Joshua Disbrow
CEO | Chief Executive Officer | 49 | 15-04-15 |
John Donofrio
BRD | Director/Board Member | 56 | 16-07-11 |
Carl Dockery
BRD | Director/Board Member | 61 | 16-04-12 |
Abhinav Jain
BRD | Director/Board Member | 33 | 23-06-11 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,972,327 | 5,773,410 ( 96.67 %) | 0 | 96.67 % |
Company contact information
Aytu Biopharma, Inc.
7900 East Union Avenue Suite 920
80237, Englewood
+720 437 6580
http://www.aytubio.com![address Aytu Bioscience Inc](https://cdn.zonebourse.com/static/address/38209285.png)
Sector
Sales per Business
Sales per region
1st Jan change | Capi. | |
---|---|---|
+62.66% | 854B | |
+40.42% | 636B | |
-4.37% | 361B | |
+17.16% | 324B | |
+9.87% | 301B | |
+15.66% | 247B | |
+4.21% | 230B | |
+17.90% | 228B | |
+14.86% | 177B |